ArticleMaterials today. Bio2026
Electrospun core-shell nanofibres embedding drug nanocrystals for long-acting mucosal delivery.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral mucositis (OM) is a common and painful complication of cancer therapies, compromising oral functions and quality of life. Traditional local treatments are limited by rapid clearance, poor local drug availability, and frequent reapplication, highlighting the need for mucoadhesive polymeric platforms enabling localized and sustained drug delivery. In this study, naringenin-nanocrystals (NAR-NCs) were produced via wet media milling to enhance NAR solubility and dissolution and subsequently encapsulated into core-shell electrospun nanofibres (NFs), with a hydrophilic poly(vinyl alcohol) (PVA)/Sangelose® (SG) core for NAR-NC stabilization and a polycaprolactone (PCL) shell for controlled release. A mucoadhesive coating composed of ethyl cellulose (EC) and SG was applied to the NAR-NC_NFs to prolong mucosal residence, protect against mechanical stress, and facilitate buccal administration. NAR-NCs exhibited a mean hydrodynamic diameter of ∼280 nm, narrow size distribution, high stability over 10 days, and a 3.6-fold increase in saturation solubility compared to raw NAR. Core-shell NFs displayed uniform, bead-free morphology with clear core-shell architecture. NAR-NCs encapsulated within NFs preserved their size after fibres dissolution, within the 200-500 nm range, suitable for buccal application and maintained tensile properties comparable to unloaded NFs. Release studies demonstrated that NAR-NCs dissolved rapidly (∼45 min), NAR-NCs_core NFs provided controlled release over 6 h, and the complete NAR-NCs_NFs system prolonged drug release up to 72 h. The system also demonstrated preliminary anti-inflammatory properties, as confirmed by IL-8 enzyme-linked immunosorbent assay (ELISA). The EC/SG_NFs prototypes maintained normal human dermal fibroblasts (NHDF) viability above 95%, supporting their suitability as a mucoadhesive, mechanically robust and biocompatible platform for oral mucositis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.